BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O'Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA, Parameswaran L, Corcoran AT, Rohatgi A, Wronska MW, Wu X, Srinivasan R, Deng FM, Filardo TD, Pendse J, Blaser SB, Whyte O, Gallagher JM, Thomas OE, Ramos D, Sturm-Reganato CL, Fong CC, Daus IM, Payoen AG, Chiofolo JT, Friedman MT, Wu DW, Jacobson JL, Schneider JG, Sarwar UN, Wang HE, Huebinger RM, Dronavalli G, Bai Y, Grimes CZ, Eldin KW, Umana VE, Martin JG, Heath TR, Bello FO, Ransford DL, Laurent-Rolle M, Shenoi SV, Akide-Ndunge OB, Thapa B, Peterson JL, Knauf K, Patel SU, Cheney LL, Tormey CA, Hendrickson JE; CONTAIN COVID-19 Consortium for the CONTAIN COVID-19 Study Group . Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial. JAMA Intern Med 2021. [PMID: 34901997 DOI: 10.1001/jamainternmed.2021.6850] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Senefeld JW, Gorman EK, Johnson PW, Moir ME, Klassen SA, Carter RE, Paneth NS, Sullivan DJ, Morkeberg OH, Wright RS, Fairweather D, Bruno KA, Shoham S, Bloch EM, Focosi D, Henderson JP, Juskewitch JE, Pirofski L, Grossman BJ, Tobian AA, Franchini M, Ganesh R, Hurt RT, Kay NE, Parikh SA, Baker SE, Buchholtz ZA, Buras MR, Clayburn AJ, Dennis JJ, Diaz Soto JC, Herasevich V, Klompas AM, Kunze KL, Larson KF, Mills JR, Regimbal RJ, Ripoll JG, Sexton MA, Shepherd JR, Stubbs JR, Theel ES, van Buskirk CM, van Helmond N, Vogt MN, Whelan ER, Wiggins CC, Winters JL, Casadevall A, Joyner MJ. Mortality rates among hospitalized patients with COVID-19 treated with convalescent plasma A Systematic review and meta-analysis.. [DOI: 10.1101/2023.01.11.23284347] [Reference Citation Analysis]
2 Al-Hatamleh MAI, Abusalah MA, Hatmal MM, Alshaer W, Ahmad S, Mohd-Zahid MH, Rahman ENSEA, Yean CY, Alias IZ, Uskoković V, Mohamud R. Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. J Taibah Univ Med Sci 2022. [PMID: 36570799 DOI: 10.1016/j.jtumed.2022.11.007] [Reference Citation Analysis]
3 Root HB, Gilleskie M, Lu CH, Gilmore A, Evans M, Nelson BG, Johnson W, Gurney B, Kuruc J, Markmann AJ, Barzin AH, Wohl DA, Fischer WA, Park YA, Weiss S, Napravnik S, Baric R, de Silva AM, Lachiewicz AM, van Duin D, Margolis DM, Herce ME, Bartelt LA. Evaluation of a COVID-19 convalescent plasma program at a U.S. academic medical center. PLoS One 2022;17:e0277707. [PMID: 36480499 DOI: 10.1371/journal.pone.0277707] [Reference Citation Analysis]
4 Pons S, Uhel F, Frapy E, Sérémé Y, Zafrani L, Aschard H, Skurnik D. How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response? Stem Cell Rev Rep 2022;:1-16. [PMID: 36422774 DOI: 10.1007/s12015-022-10477-y] [Reference Citation Analysis]
5 Kimber C, Lamikanra AA, Geneen LJ, Sandercock J, Dorée C, Valk SJ, Estcourt LJ. A systematic review of the safety and efficacy of convalescent plasma or immunoglobulin treatment for people with severe respiratory viral infections due to coronaviruses or influenza. Transfusion Medicine 2022. [DOI: 10.1111/tme.12942] [Reference Citation Analysis]
6 Kiss-Dala N, Szabo BG, Lakatos B, Reti M, Szlavik J, Valyi-Nagy I. Use of convalescent plasma therapy in hospitalised adult patients with non-critical COVID-19: a focus on the elderly from Hungary. Geroscience 2022;44:2427-45. [PMID: 36367599 DOI: 10.1007/s11357-022-00683-4] [Reference Citation Analysis]
7 Bertini CD, Khawaja F, Sheshadri A. COVID-19 in the Immunocompromised Host. Clinics in Chest Medicine 2022. [DOI: 10.1016/j.ccm.2022.11.012] [Reference Citation Analysis]
8 Casadevall A, Henderson JP. COVID-19 Convalescent Plasma and Concomitant Therapies in PassITON. Chest 2022;162:e284-e285. [DOI: 10.1016/j.chest.2022.07.028] [Reference Citation Analysis]
9 Celikgil A, Massimi AB, Nakouzi A, Herrera NG, Morano NC, Lee JH, Yoon HA, Garforth SJ, Almo SC. SARS-CoV-2 multi-antigen protein microarray for detailed characterization of antibody responses in COVID-19 patients.. [DOI: 10.1101/2022.10.14.512324] [Reference Citation Analysis]
10 Villanueva C, Neyra I, Sagastegui A, Chunga A, Oyanguren M, Guillermo-roman M, Soto-ordoñez S, Maguiña JL, Hurtado-roca Y, Soto-becerra P, Araujo-castillo RV. Efficacy and safety of convalescent plasma versus standard care in hospitalized patients with COVID-19 from the Peruvian Social Security Health System: open-label, randomized, controlled clinical trial.. [DOI: 10.1101/2022.09.21.22280195] [Reference Citation Analysis]
11 Bartelt LA, Markmann AJ, Nelson B, Keys J, Root H, Henderson HI, Kuruc J, Baker C, Bhowmik DR, Hou YJ, Premkumar L, Cornaby C, Schmitz JL, Weiss S, Park Y, Baric R, de Silva AM, Lachiewicz A, Napravnik S, van Duin D, Margolis DM. Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study. mBio 2022;:e0175122. [PMID: 36135380 DOI: 10.1128/mbio.01751-22] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Battaglini D, Cruz F, Robba C, Pelosi P, Rocco PRM. Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics. Expert Opin Investig Drugs 2022. [PMID: 36047644 DOI: 10.1080/13543784.2022.2120801] [Reference Citation Analysis]
13 Zhou CK, Bennett MM, Villa CH, Hammonds KP, Lu Y, Ettlinger J, Priest EL, Gottlieb RL, Davis S, Mays E, Clarke TC, Shoaibi A, Wong H, Anderson SA, Kelly RJ. Multi-center matched cohort study of convalescent plasma for hospitalized patients with COVID-19. PLoS ONE 2022;17:e0273223. [DOI: 10.1371/journal.pone.0273223] [Reference Citation Analysis]
14 Estcourt LJ, Cohn CS, Pagano MB, Iannizzi C, Kreuzberger N, Skoetz N, Allen ES, Bloch EM, Beaudoin G, Casadevall A, Devine DV, Foroutan F, Gniadek TJ, Goel R, Gorlin J, Grossman BJ, Joyner MJ, Metcalf RA, Raval JS, Rice TW, Shaz BH, Vassallo RR, Winters JL, Tobian AAR. Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma. Ann Intern Med 2022. [PMID: 35969859 DOI: 10.7326/M22-1079] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
15 Lanza F, Monaco F, Ciceri F, Cairoli R, Sacchi MV, Guidetti A, Marchetti M, Massaia M, Arcaini L, Krampera M, Mohamed S, Gherlinzoni F, Mecucci C, Gentile M, Romano I, Venditti A, Ruggeri M, Ferrero D, Coviello E, Fabbri E, Corradini P, Passamonti F. Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study. Hematol Oncol 2022;40:857-63. [PMID: 35932208 DOI: 10.1002/hon.3060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Tse K, Chen Q, Padilla A, Martinez K, Salazar A, Aidikoff J, Soliven S, Sintef A, Palmer-toy D, Platz B, Shafi H, Zemek A. Lessons learned from the use of COVID-19 convalescent plasma at Kaiser Permanente. Journal of Allergy and Clinical Immunology: Global 2022. [DOI: 10.1016/j.jacig.2022.07.003] [Reference Citation Analysis]
17 Qian Z, Zhang Z, Ma H, Shao S, Kang H, Tong Z. The efficiency of convalescent plasma in COVID-19 patients: A systematic review and meta-analysis of randomized controlled clinical trials. Front Immunol 2022;13:964398. [DOI: 10.3389/fimmu.2022.964398] [Reference Citation Analysis]
18 Belov A, Huang Y, Villa CH, Whitaker BI, Forshee R, Anderson SA, Eder A, Verdun N, Joyner MJ, Wright SR, Carter RE, Hung DT, Homer M, Hoffman C, Lauer M, Marks P; Broad Institute COVID-19 Antibody Team. Early administration of COVID-19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy. Am J Hematol 2022;97:770-9. [PMID: 35303377 DOI: 10.1002/ajh.26531] [Reference Citation Analysis]
19 Wieczorek L, Zemil M, Merbah M, Dussupt V, Kavusak E, Molnar S, Heller J, Beckman B, Wollen-roberts S, Peachman KK, Darden JM, Krebs S, Rolland M, Peel SA, Polonis VR. Evaluation of Antibody-Dependent Fc-Mediated Viral Entry, as Compared With Neutralization, in SARS-CoV-2 Infection. Front Immunol 2022;13:901217. [DOI: 10.3389/fimmu.2022.901217] [Reference Citation Analysis]
20 Bartelt LA, Markmann AJ, Nelson B, Keys J, Root H, Henderson HI, Kuruc J, Baker C, Bhowmik DR, Hou YJ, Premkumar L, Cornaby C, Schmitz JL, Weiss S, Park Y, Baric R, de Silva AM, Lachiewicz A, Napravnik S, van Duin D, Margolis DM. Outcomes of convalescent plasma with defined high- versus lower-neutralizing antibody titers against SARS-CoV-2 among hospitalized patients: CoronaVirus Inactivating Plasma (CoVIP), double-blind phase 2 study.. [DOI: 10.1101/2022.04.29.22274387] [Reference Citation Analysis]
21 Strohl WR, Ku Z, An Z, Carroll SF, Keyt BA, Strohl LM. Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. BioDrugs 2022. [PMID: 35476216 DOI: 10.1007/s40259-022-00529-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
22 Focosi D, Franchini M, Pirofski LA, Burnouf T, Paneth N, Joyner MJ, Casadevall A. COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes. Clin Microbiol Rev 2022;:e0020021. [PMID: 35262370 DOI: 10.1128/cmr.00200-21] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]
23 Troxel AB, Petkova E, Goldfeld K, Liu M, Tarpey T, Wu Y, Wu D, Agarwal A, Avendaño-solá C, Bainbridge E, Bar KJ, Devos T, Duarte RF, Gharbharan A, Hsue PY, Kumar G, Luetkemeyer AF, Meyfroidt G, Nicola AM, Mukherjee A, Ortigoza MB, Pirofski L, Rijnders BJA, Rokx C, Sancho-lopez A, Shaw P, Tebas P, Yoon H, Grudzen C, Hochman J, Antman EM. Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19: A Meta-analysis. JAMA Netw Open 2022;5:e2147331. [DOI: 10.1001/jamanetworkopen.2021.47331] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
24 Focosi D, Franchini M, Pirofski L, Burnouf T, Paneth N, Joyner MJ, Casadevall A. COVID-19 convalescent plasma and randomized clinical trials: explaining conflicting outcomes and finding signals of efficacy.. [DOI: 10.1101/2021.09.07.21263194] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]